INTRODUCTION

Hereditary Cancer Syndromes are caused by faulty changes in genes called as “Hereditary Mutations”. These can be passed down from parent to child and cause cancer to run in the family, making it Hereditary Cancer.

ScreenGeneTM by Datar Cancer Genetics Limited analyzes genes to help patients understand their risk for the most common hereditary cancers, including breast, ovarian, colorectal, pancreatic and other cancers.

Features of Screengene

  • Simultaneous analysis of multiple cancer predisposition genes
  • More time and cost-effective than single gene testing for patients suspicious for multiple hereditary cancer syndromes
  • A greater likelihood of identifying a hereditary cause for cancer
  • Avoidance of false negative assurance given by limited genetic screening, which can miss risk-causing genetic mutations in other genes
  • A complete diagnostic work-up in a timely fashion without multiple follow-up visits for additional test results

FOR WHOM?

ScreengeneTM is considered in cancer patients with..

Cancer (e.g., Breast / Ovarian / Endometrial / Colorectal) at an early age (50 years or younger)

Two or more different types of cancer

Cancer in both organs in a set of paired organs, e.g., Bilateral Breast Cancer

Unusual presentation of cancer, e.g., Breast cancer in a Male

Cancer with specific features, e.g., Triple-Negative Breast Cancer, MSI high Colorectal Cancer

Cancer under treatment to identify therapy relevant hereditary gene mutation, e.g., BRCA and PARP inhibitors

Previously identified hereditary cancer gene mutation in the family

One or more family members with cancer on the same side of the family

A family member with a typical / unusual presentation or multiple cancers in the same person

How it will help you?

If ScreenGeneTM confirms the presence of any gene mutation associated with Hereditary Cancer risk, several cancer prevention options may become feasible

A person may opt for risk reducing surgeries such as mastectomy or oophorectomy, if there is a family history of cancer and the person has specific mutations

Increased surveillance may detect cancer at an earlier, more treatable stage, when outcomes are better

Surveillance frequency can be determined, depending on genetic test results, with starting of cancer screening at an earlier age and at an increased frequency in mutation carriers

Targeted surveillance reduces medical costs and gives preemptive advantage before onset of the disease

Improved compliance with tailored screening recommendation and preventive measures

Counseling of at-risk family members, to undergo relevant genetic test to identify their predisposition

Clinical evidence

Increase in lifetime cancer risk for people with an identified hereditary cancer gene mutation

Women who carry a mutation in either of the BRCA genes have a condition called Hereditary Breast Ovarian Cancer (HBOC) syndrome. Approximately, 10-15% of Ovarian cancer and 10% of Breast cancer cases, are caused by mutations in the BRCA1 or BRCA2 genes. In addition, some more genes have been found to be responsible for hereditary Breast or Ovarian cancer. Furthermore, mutation carriers who have already been diagnosed with cancer have a significantly increased risk of developing a second cancer in the future.

About 7 to 9 out of 10 patients with Lynch syndrome develop bowel cancer. Such individuals are at a higher risk of developing Colorectal, Uterine (endometrial), Ovarian, and Gastric (stomach) cancers. Many other cancers like Melanoma, Retinoblastoma, Wilm’s tumour, etc. have been established to have hereditary association.

Available panels

Hereditary Screening Panels are available for following cancers

Recommendations

Recommendations for Hereditary Cancer Screening